RT @faheema_hasan: Beautiful review of HLH on @NEJM from history to management of primary and secondary HLH In the revised HLH 2024 criteri…

@gulderenesra @ValentinOrtizMD @TheEBMT @EHA_Hematology @TheEBMT_Trainee @young_eha Congrats! 👏👏

RT @7eyeblink: It is always a pleasure listening to you @gloria_iacoboni !! different strategies and their impact pre/post CAR-T in NHL: be…

RT @mercedesmontoro: Creation of a comprehensive nursing care program for follow-up of CAR-T Cell therapy patients #PilarAyora @hematoclini…

RT @HematoRules: Pere Barba @Hemato_Vhebron on #CART25 Excellent presentation and very promising results @TheEBMT @young_eha @EHA_Hemato…

CNS relapse in high-grade B-cell lymphoma with MYC and BCL2 rearrangements and dark-zone signature–expressing DLBCL | Blood | American Society of Hematology

RT @BloodAdvances: Forty-one percent of referrals in the community were unable to access anti-CD19+ CARTs for NHL between 2018 and 2022. ht…

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation | Blood | American Society of Hematology The 2-year PFS of 72% compares favorably with previously reported outcomes withCIT in TP53-mutant MCL

@A_Trasplantes @HospitalUVRocio @cid_manuela @coordtxSevHuelv @DagaDomingo @donantessevilla @ONT_esp @saludand @ToiAlvarez11 Enhorabuena!

RT @Irene_sanchezv: Hoy 27/01 el Ministerio ha publicado las respuestas provisionales del #2MIR25, aunque la noche del MIR ya hice algunas…

RT @BloodAdvances: Among 259 patients receiving CAR T cells for lymphoma, 26% had weight loss, defined as >5% reduction in body mass index…

@luis_aranzabal @GipuzkoaKirolak @atletismogaf A ze eskola sortzen ari zaren Luis! Mila esker zure lan ederragatik!

RT @luis_aranzabal: Euskadiko txapelketa absolutua atzo 💥 Ander🥇5,36 PB + Europako U23 txapelketarako gutxieneko marka Asier 🥈5,20 PB +…

RT @KRejeski: Great to see prospective validation of the CAR HEMATOTOX by our Italian colleagues! Association with: - G3+ late ICAHT - O…

RT @sehh_es: 📢@ixazebe resume lo más destacado en #LDCGB, en esta nueva píldora de las #CLAVESdeASH⤵️ 📹Conoce lo último presentado en el c…

RT @geltamo: 📢¡Atención! @GELTAMO ha publicado su Guía de manejo de Anticuerpos Biespecíficos en #LinfomasNoHodgkinB. Ya está disponible pa…

@DrRaulCordoba @ANECAinfo @CienciaGob Enhorabuena!

RT @Abdallah81MD: 🚨 1/Idecabtagene vicleucel 🚗 or ciltacabtagene autoleucel 🚙 for RRMM! This study aims to directly compare the efficacy a…

RT @DrRaulCordoba: #Hematology Assessment of fitness for #bleomycin use and management of bleomycin pulmonary toxicity in patients with cla…

RT @sehh_es: 🙌🏼 Éxito en el primer día de la reunión #PostASH_ES en #Valencia. 📲Síguenos en redes para conocer lo último en #hematología tr…